Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
natrunix + methotrexate
- Development stage
- Discontinued
- Lead developer
- XBiotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous
01
Overview
Natrunix + methotrexate is a combination therapy consisting of Natrunix, a True Human monoclonal antibody that specifically targets and blocks interleukin-1 alpha (IL-1α), administered alongside methotrexate, a disease-modifying antirheumatic drug. This combination is being investigated for the treatment of rheumatoid arthritis, particularly in patients who have had an inadequate response to methotrexate alone.
02
Targets
DHFR (Dihydrofolate reductase)IL1A (Interleukin 1 alpha)
Beyond the preview
Go deeper on natrunix + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on natrunix + methotrexate.